The influence of gut microbiota on drug metabolism and toxicity

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 1, 2016, Pages 31-40

  Li, Houkai ^a   He, Jiaojiao ^a   Jia, Wei ^a,b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

drug metabolism; efficacy; gut microbiota; toxicity

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DIGOXIN; DRUG METABOLIZING ENZYME; FIRTECAN; FIRTECAN GLUCURONIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; MEVINOLIN; PARACETAMOL; SIMVASTATIN; DRUG;

COLORECTAL CANCER; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TOXICITY; ENTEROPATHY; GENETIC VARIABILITY; HEART FAILURE; HOST PATHOGEN INTERACTION; HUMAN; INTESTINE FLORA; LIVER TOXICITY; METABOLIC REGULATION; MICROBIAL METABOLISM; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; TREATMENT RESPONSE; ADVERSE DRUG REACTION; ANIMAL; GASTROINTESTINAL TRACT; METABOLISM; METABOLOMICS; METAGENOMICS; MICROBIOLOGY; PROCEDURES;

ANIMALS; DRUG DESIGN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; METABOLOMICS; METAGENOMICS; PHARMACEUTICAL PREPARATIONS;

EID: 84954379199     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2016.1121234     Document Type: Review

References (76)

1. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312 (5778):1355-1359.
2. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65.
3. Jia W, Li H, Zhao L, et al. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov. 2008;7(2):123-129.
4. Kang MJ, Kim HG, Kim JS, et al. The effect of gut microbiota on drug metabolism. Expert Opin Drug Metab Toxicol. 2013;9(10):1295-1308.
5. Rajilic-Stojanovic M, Smidt H, De Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol. 2007;9(9):2125-2136.
6. Saad R, Rizkallah MR, Aziz RK. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 2012;4(1):16.
7. Haiser HJ, Turnbaugh PJ. Developing a metagenomic view of xenobiotic metabolism. Pharmacol Res. 2013;69(1): 21-31.
8. Clayton TA, Baker D, Lindon JC, et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA. 2009;106 (34):14728-14733.
9. Haiser HJ, Gootenberg DB, Chatman K, et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013;341(6143):295-298.
10. Westman EL, Canova MJ, Radhi IJ, et al. Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012;19 (10):1255-1264.
11. Lindenbaum J, Rund DG, Butler VP Jr., et al. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med. 1981;305(14):789-794.
12. Goldin BR, Peppercorn MA, Goldman P. Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J Pharmacol Exp Ther. 1973;186 (1):160-166.
13. Koch RL, Goldman P. The anaerobic metabolism of metronidazole forms N-(2- hydroxyethyl)-oxamic acid. J Pharmacol Exp Ther. 1979;208(3):406-410.
14. Aura AM, Mattila I, Hyotylainen T, et al. Drug metabolome of the simvastatin formed by human intestinal microbiota in vitro. Mol Biosyst. 2011;7(2):437-446.
15. Yoo DH, Kim IS, Van Le TK, et al. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 2014;42(9):1508-1513.
16. Mikov M, Caldwell J, Dolphin CT, et al. The role of intestinal microflora in the formation of the methylthio adduct metabolites of paracetamol. Studies in neomycin- pretreated and germ-free mice. Biochem Pharmacol. 1988;37(8):1445-1449.
17. Shu YZ, Kingston DG, Van Tassell RL, et al. Metabolism of levamisole, an anticolon cancer drug, by human intestinal bacteria. Xenobiotica. 1991;21(6):737-750.
18. Jin MJ, Kim U, Kim IS, et al. Effects of gut microflora on pharmacokinetics of hesperidin: a study on non-antibiotic and pseudo-germ-free rats. J Toxicol Environ Health A. 2010;73(21-22):1441-1450.
19. Lee NK, Choi SH, Park SH, et al. Antiallergic activity of hesperidin is activated by intestinal microflora. Pharmacology. 2004;71(4):174-180.
20. Caldwell J, Hawksworth GM. The demethylation of methamphetamine by intestinal microflora. J Pharm Pharmacol. 1973;25(5):422-424.
21. Basit AW, Newton JM, Lacey LF. Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm. 2002;237 (1-2):23-33.
22. Watanabe K, Yamashita S, Furuno K, et al. Metabolism of omeprazole by gut flora in rats. J Pharm Sci. 1995;84(4):516-517.
23. Meuldermans W, Hendrickx J, Mannens G, et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos. 1994; 22(1):129-138.
24. Wadworth AN, Olsalazine FA. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991;41(4):647-664.
25. Strong HA, Renwick AG, George CF, et al. The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Xenobiotica. 1987;17(6):685-696.
26. Holt R. The bacterial degradation of chloramphenicol. Lancet. 1967;1 (7502):1259-1260.
27. Tozaki H, Emi Y, Horisaka E, et al. Metabolism of peptide drugs by the microorganisms in rat cecal contents. Biol Pharm Bull. 1995;18(6):929-931.
28. Shim SB, Kim NJ, Kim DH. Beta-glucuronidase inhibitory activity and hepatoprotective effect of 18 beta-glycyrrhetinic acid from the rhizomes of Glycyrrhiza uralensis. Planta Med. 2000;66(1):40-43.
29. Akao T, Hayashi T, Kobashi K, et al. Intestinal bacterial hydrolysis is indispensable to absorption of 18-beta-glycyrrhetic acid after oral-administration of glycyrrhizin in rats. J Pharm And Pharmacol. 1994;46(2):135-137.
30. Takeno S, Sakai T. Involvement of the intestinal microflora in nitrazepaminduced teratogenicity in rats and its relationship to nitroreduction. Teratology. 1991;44(2):209-214.
31. Harris BE, Manning BW, Federle TW, et al. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrob Agents Chemother. 1986;29(1):44-48.
32. Lavrijsen K, Van Dyck D, Van Houdt J, et al. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab Dispos. 1995;23(3):354-362.
33. Tralau T, Sowada J, Luch A. Insights on the human microbiome and its xenobiotic metabolism: what is known about its effects on human physiology? Expert Opin Drug Metab Toxicol. 2015;11(3):411-425.
34. Li H, Jia W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther. 2013;94(5):574-581.
35. Nakayama H, Kinouchi T, Kataoka K, et al. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5- fluorouracil. Pharmacogenetics. 1997;7 (1):35-43.
36. Mao B, Li D, Zhao J, et al. In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014;62 (45):10970-10977.
37. Sahota SS, Bramley PM, Menzies IS. The fermentation of lactulose by colonic bacteria. J Gen Microbiol. 1982;128(2):319-325.
38. Trinh HT, Joh EH, Kwak HY, et al. Antipruritic effect of baicalin and its metabolites, baicalein and oroxylin A, in mice. Acta Pharmacol Sin. 2010;31(6):718-724.
39. Kang MJ, Ko GS, Oh Do G, et al. Role of metabolism by intestinal microbiota in pharmacokinetics of oral baicalin. Arch Pharm Res. 2014;37(3):371-378.
40. Matthies A, Clavel T, Gutschow M, et al. Conversion of daidzein and genistein by an anaerobic bacterium newly isolated from the mouse intestine. Appl Environ Microbiol. 2008;74(15):4847-4852.
41. Renouf M, Hendrich S. Bacteroides uniformis is a putative bacterial species associated with the degradation of the isoflavone genistein in human feces. J Nutr. 2011;141(6):1120-1126.
42. Akao T, Kida H, Kanaoka M, et al. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb-1 from Panax ginseng. J Pharm And Pharmacol. 1998;50(10):1155-1160.
43. Matthies A, Loh G, Blaut M, et al. Daidzein and genistein are converted to equol and 5- hydroxy-equol by human intestinal Slackia isoflavoniconvertens in gnotobiotic rats. J Nutr. 2012;142(1):40-46.
44. Schneider H, Simmering R, Hartmann L, et al. Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria. J Appl Microbiol. 2000;89(6):1027-1037.
45. Di L. The role of drug metabolizing enzymes in clearance. Expert Opin Drug Metab Toxicol. 2014;10(3):379-393.
46. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13(4):260-270.
47. Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J. 1966;2(5512):497-499.
48. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42 (6):1364-1372.
49. Smith EA, Macfarlane GT. Formation of phenolic and indolic compounds by anaerobic bacteria in the human large intestine. Microb Ecol. 1997;33(3):180-188.
50. Lee SH, An JH, Lee HJ, et al. Evaluation of pharmacokinetic differences of acetaminophen in pseudo germ-free rats. Biopharm Drug Dispos. 2012;33(6):292-303.
51. Gamage N, Barnett A, Hempel N, et al. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci. 2006;90(1):5-22.
52. Possamai LA, McPhail MJ, Khamri W, et al. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity. Liver Int. 2015;35(3):764-773.
53. Jacobs WAHA. The relationship between the structure and the biological action of the cardiac glucosides. J Biol Chem. 1927;74:787-793.
54. Vick RL KJJ, Acheson GH. Effects of dihydroouabain, dihydrodigoxin and dihydrodigitoxin on the heart-lung preparation of the dog. J Pharmacol Exp Ther. 1957;121:330-339.
55. Saha JR, Butler VP Jr., Neu HC, et al. Digoxin-inactivating bacteria: identification in human gut flora. Science. 1983;220(4594):325-327.
56. Wilson ID. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc Natl Acad Sci USA. 2009;106(34):14187-14188.
57. Kajinami K, Akao H, Polisecki E, et al. Pharmacogenomics of statin responsiveness. Am J Cardiol. 2005;96 (9A):65K-70K. discussion 34K-35K.
58. Charlab R, Zhang L. Pharmacogenomics: historical perspective and current status. Methods Mol Biol. 2013;1015:3-22.
59. Yip LY, Chan EC. Investigation of hostgut microbiota modulation of therapeutic outcome. Drug Metab Dispos. 2015;43 (10):1619-1631.
60. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336 (6086):1268-1273.
61. Sistigu A, Viaud S, Chaput N, et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol. 2011;33 (4):369-383.
62. Schiavoni G, Sistigu A, Valentini M, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011;71(3):768-778.
63. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34(2):336-344.
64. Viaud S, Flament C, Zoubir M, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res. 2011;71(3):661-665.
65. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971-976.
66. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967-970.
67. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001;19(5):1501-1518.
68. Stringer AM, Gibson RJ, Logan RM, et al. Faecal microflora and beta-glucuronidase expression are altered in an irinotecaninduced diarrhea model in rats. Cancer Biol Ther. 2008;7(12):1919-1925.
69. Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996;56(16):3752-3757.
70. Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330(6005):831-835.
71. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2): 227-239.
72. Barber MJ, Mangravite LM, Hyde CL, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One. 2010;5(3):e9763.
73. Kaddurah-Daouk R, Baillie RA, Zhu H, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS One. 2011;6(10):e25482.
74. Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21(4):504-516.
75. Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA. 2009;106(10):3698-3703.
76. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336(6086):1262-1267.